August 5, 2009 — The US Food and Drug Administration (FDA) has approved a long-acting, once-monthly formulation of paliperidone palmitate injection (Invega Sustenna, Janssen, a division of ...

The Food and Drug Administration has approved Invega Hafyera ™ (paliperidone palmitate), an every 6-month injection, for the treatment of schizophrenia in adults. Invega Hafyera is a long-acting ...

If you have schizophrenia, your doctor might suggest Invega Trinza as a treatment option for you. Invega Trinza is a prescription medication that treats schizophrenia in adults. It can be used in ...

If approved, paliperidone palmitate 3-monthly injection will be the first once-every-three-months treatment for schizophrenia in the UK Janssen UK announced today that the Committee for Medicinal ...

TITUSVILLE, N.J., May 24 /PRNewswire/ --New data on INVEGA® SUSTENNA® (paliperidone palmitate), a long-acting injectable medicine for schizophrenia, and new data on RISPERDAL® CONSTA® (risperidone ...

TITUSVILLE, N.J., May 19, 2015 / PR Newswire / — There's a new treatment option for schizophrenia – INVEGA TRINZA™ (three-month paliperidone palmitate), the first and only schizophrenia medication to ...

Janssen Launches Phase 3 Invokana Trial in Diabetic Nephropathy Janssen announced the availability of Invega Trinza (paliperidone palmitate) extended-release injectable suspension for the treatment of ...

The full CMI on the next page has more details. If you are worried about using this medicine, speak to your doctor or pharmacist. INVEGA SUSTENNA contains the active ingredient paliperidone palmitate.

Janssen announced today that the Scottish Medicines Consortium (SMC) has accepted paliperidone palmitate (Trevicta ®) for use within NHS Scotland. Paliperidone palmitate (Trevicta ®), a 3-monthly ...